I-BASE HIV TREATMENT BULLETINImportant note: Information in this article was accurate in November 2003. The state of the art may have changed since the publication date.
Click here to return to I-BASE main menu
DonateNow
Print this Article

Women have a greater immunological response to effective HAART

HIV Treatment Bulletin - November 2003
Polly Clayden, HIV i-Base


A retrospective analysis of data from 53 women and 60 men, published in the 5 September issue of AIDS, compared the immunological responses of women to men in patients with suppressed viral load <400 copies/ml at 24 weeks.

Of the patients analysed, 49% were described as African American, 30% Hispanic and 21% Caucasian. Thirty percent of both men and women were antiretroviral naïve. All patients in both groups received combination therapy.

Sixty one percent received a protease inhibitor and two nucleoside analogues; 30%, an NNRTI and two nucleosides and 5% used triple nucleosides.

On initiation of therapy, CD4 counts and viral load were similar in both groups but the mean CD4 count change was much greater in women then in men, 170 cells and 100 cells respectively (p=0.0074). Multivariate analysis failed to show any contribution of either the patients’ age or initial viral load.

The investigators report: “Our data reveal that, among virological responders, women have a greater response.” They report that the reasons for this are unclear and they note: “The larger increase in CD4 T-cells seen in women suggests that significant pathological differences may exist between the two sexes.” They add: “Our findings warrant further investigation of the immunological differences between the two sexes.”

Ref: Finkel DG, John G, Holland B et al. Women have a greater immunological response to effective virological HIV-1 therapy - AIDS. 2003 Sep 5;17(13):2009-11.

031110
IB30409-23


©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.